ArticleBMC pulmonary medicine2026
Determinants of adherence to sirolimus among lymphangioleiomyomatosis patients.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLymphangioleiomyomatosis (LAM) is a low-grade malignant neoplasm characterized by multisystem involvement. Patients with LAM require long-term sirolimus therapy to slow disease progression, yet poor adherence to this medication may lead to reduced lung function and disease deterioration.
objectiveThe objective of this study is to comprehensively characterize sirolimus adherence in patients with LAM. Specifically, it aims to identify factors associated with poor adherence, explore determinants of self-reported adherence, and compare changes in pulmonary function over 2 years across adherence groups.
methodsWe conducted a questionnaire survey of patients diagnosed with LAM (n = 133). We used the 8-item Morisky Medication Adherence Scale (MMAS-8) to assess medication adherence, the Brief Illness Perception Questionnaire (BIPQ) to assess illness perceptions, the Social Support Rating Scale (SSRS) to assess social support, and the Hospital Anxiety and Depression Scale (HADS) to assess anxiety and depressive symptoms. Multivariate logistic regression was then performed to identify risk factors influencing sirolimus adherence among LAM patients. Furthermore, we compared changes in lung function over the two-year follow-up period.
resultsIn our cohort, 20.3% of LAM patients demonstrated high medication adherence, 41.5% moderate adherence, and 38.1% poor adherence. Additionally, educational level, FEV1/FVC (% predicted), the number of adverse drug reactions ≥ 3, BIPQ scores and anxiety symptoms are associated with medication adherence. Furthermore, patients with better medication adherence showed greater improvements in lung function, exercise endurance, and disease activity than those with poor adherence.
conclusionOver one-third of LAM patients reported poor medication adherence. High FEV1/FVC (% predicted), high BIPQ scores, comorbid anxiety, and low educational level are risk factors. These may help identify LAM patients with poor medication adherence early.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.